THE EFFECT OF ANTI-CANCER PREPARATION WITH A SELECTIVE EFFECT UKRAIN (NSC 631570) ON WOMEN REPRODUCTIVE CANCERS

doi:10.4066/2591-7951-C3-008

THE EFFECT OF ANTI-CANCER PREPARATION WITH A SELECTIVE EFFECT UKRAIN (NSC 631570) ON WOMEN REPRODUCTIVE CANCERS

Joint Event on World Congress on BREAST CANCER, GYNECOLOGY AND WOMEN HEALTH & Annual Conference on ORTHOPEDICS AND RHEUMATOLOGY
September 06-07, 2018 | Bangkok ,Thailand

Wassil Nowicky

Nowicky Pharma, Austria

Scientific Tracks Abstracts : Arch Gen Intern Med

DOI: 10.4066/2591-7951-C3-008

Abstract:

First indications on the selective effect of NSC‐631570 on the cancer cells were provided in an early study when different oxygen consumption by normal liver cells and Ehrlich’s tumor ascitic cells after the incubation with NSC‐631570 was re-vealed. There was a report on the success-ful using NSC‐631570 in the treatment of ovarian cancer. Also, in the tests of Na-tional Cancer Institute NSC‐631570 was toxic against all ovarian cancer cell lines tested. NSC‐631570 induced apoptosis in a panel of cancer cell lines (ovarial and cervical cancer HeLa, HeKB, HeKS32, HeBcl3, HeNFR and HeIKK, human colon cancer SW480, human renal carcinoma HEK293, human osteosarcoma MG‐63) by activating the caspases of the intrinsic cell death pathway. Interestingly, non‐transformed fibroblasts (hTERT) cell line was insensitive to the drug. In the tests on human ovarian and cervix carcinoma cells HeLa, squamous carcinoma cells WHCO5, normal kidney cell line Graham 293, and transformed kidney cell line Vero from African green monkey, NSC‐631570 inhibited the tubulin polymerization and caused a metaphase block in cancer cells which is characterized by abnormal chromosomal distribution, and results in the formation of micronuclei and in apoptosis. Recent Publications 1.Wassil Nowicky (2017). Selective and immunomodulating properties of the anticancer proton preparation on basis of greater celandine alkaloids NSC631570. J Clin Exp Oncol. DOI: 10.4172/2324-9110-C1-004.

Biography:

Wassil Nowicky is the Director of Nowicky Pharma and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radio-technical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955. He is invited as an honorable speaker to take part in many scientific international congresses and conferences in USA, Australia, Japan, UAE, Europe. He is the author of over 300 scientific articles dedicat-ed to cancer research. He is a real Member of the New York Academy of Sciences, Member of the European Union for applied immunology and of the American Association for scientific progress, honorary doctor of the Janka Kupala University in Hrodno, honorary doctor causa of the Open International University on Complex Medicine in Colombo, honorary Member of the Austrian Society of a name od Albert Schweizer.

E-mail: dr.nowicky@yahoo.de

PDF HTML